Oracle (ORCL) PT Lowered to $250 at UBS

UBS analyst Karl Keirstead lowered the price target on Oracle (NYSE: ORCL) to $250.00 (from $280.00) while maintaining a Buy rating.

The analyst commented, "Right ahead of a planned debt issuance, Oracle press-released some incremental disclosures about its funding needs in 2026, required to finance the build-out of AI infrastructure. Oracle disclosed that it will raise $45-50 billion in cash in 2026 via a roughly equal balance of debt and equity and that it remains committed to its investment grade rating. The planned debt raise of “only” $20-25 billion coupled with an equity raise of up to $20 billion will likely come as a relief to credit investors while the equity raise (which Oracle has long described as a last resort) may not be warmly received by all equity holders. We are Buy-rated and wonder if this long-awaited clarity may serve as a clearing event for the stock."

You May Also Be Interested In